14th Sep 2015 08:32
LONDON (Alliance News) - Biopharmaceutical company Biofrontera AG on Monday said it has been informed by the US Food and Drug Administration that it has accepted the new drug application filing for its Ameluz skin cancer treatment.
The application covers the use of Ameluz in combination with BF-RhodoLED medical device.
The acceptance of the application is the first step towards gaining full approval from the US regulator for using Ameluz and BF-RhodoLED in the US market.
Shares in Biofrontera were untraded early Monday, having last traded at 160.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L